Envoy Therapeutics, Inc., a recently-formed drug discovery company, has expanded its research collaboration with The Scripps Research Institute aimed at identifying new drugs for neurological and psychiatric diseases. Augmenting the collaboration Envoy and Scripps commenced in July focused on improved treatments for Parkinson’s disease, scientists at the two organizations will carry out three additional drug discovery programs over the coming year. These programs will employ Scripps-Florida’s high-throughput screening capabilities to discover compounds that modulate target proteins identified by Envoy.

Leave a Reply

Your email address will not be published. Required fields are marked *